RESEARCH &RELATED - OTHER PROJECT INFORMATION - PROJECT SUMMARY/ABSTRACT The Administrative Core (Core A) is a centralized facility designed to manage all operations related to this PPG. It facilitates the interactions between the collaborating laboratories and is located within the Center for Drug Discovery (Northeastern University). During this cycle, the Administrative Core has been functioning very effectively. Suitable modifications were made to accommodate new directions and personnel changes. The major tasks of this Core component will continue to be: a) communicate the central scientific theme to which all component projects will direct their research efforts and maintain a focused approach while fulfilling the PPG's overall specific aims;b) manage the fiscal aspects of the PPG, maintain financial records and other administrative functions;and c) promptly and properly distribute or coordinate the distribution of materials (novel ligands;other ligands developed in the PI's laboratory;receptor mutants) produced under the auspices of Core B and the other projects. The Administrative Core also takes responsibility for synchronizing the operations and communications between the individual laboratories involved in the PPG and other laboratories which interact collaboratively at no cost to the project. This effort includes recording and distributing materials produced to the participant laboratories and to the collaborating laboratories, together with maintaining and updating the data base related to this collaborative effort. Additional specific coordinating efforts include maintaining regular telephone conferences, the yearly group meeting of participants and collaborators, as well as other communications and the quarterly meetings with the Internal Advisory Committee, as well as the yearly formal meeting with the External Scientific Advisory Committee. The Administrative Core will manage the shared resources that are required for the performance of the interrelated tasks for the individual research projects. General administrative support related to this Program Project, including financial management, correspondence and preparation of reports and proposals, will also be provided by this Core Facility. The administrative portion of this grant seeks to keep all three projects and Core B focused on the overall research goals and to enhance communication between each branch of the grant. It will enhance the ability of collaborating laboratories to focus on the central PPG's overall goal which is the development of therapies for addiction and pain.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Program Projects (P01)
Project #
2P01DA009158-15A1
Application #
8742281
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
2014-09-15
Budget End
2015-06-30
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Northeastern University
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02115
Lin, Xiaoyan; Dhopeshwarkar, Amey S; Huibregtse, Megan et al. (2018) Slowly Signaling G Protein-Biased CB2 Cannabinoid Receptor Agonist LY2828360 Suppresses Neuropathic Pain with Sustained Efficacy and Attenuates Morphine Tolerance and Dependence. Mol Pharmacol 93:49-62
Slivicki, Richard A; Saberi, Shahin A; Iyer, Vishakh et al. (2018) Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit. J Pharmacol Exp Ther 367:551-563
Straiker, Alex; Dvorakova, Michaela; Zimmowitch, Anaelle et al. (2018) Cannabidiol Inhibits Endocannabinoid Signaling in Autaptic Hippocampal Neurons. Mol Pharmacol 94:743-748
Mallipeddi, Srikrishnan; Zvonok, Nikolai; Makriyannis, Alexandros (2018) Expression, Purification and Characterization of the Human Cannabinoid 1 Receptor. Sci Rep 8:2935
Slivicki, Richard A; Xu, Zhili; Kulkarni, Pushkar M et al. (2018) Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence. Biol Psychiatry 84:722-733
Li, Ai-Ling; Carey, Lawrence M; Mackie, Ken et al. (2017) Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice. J Pharmacol Exp Ther 362:296-305
Finlay, David B; Cawston, Erin E; Grimsey, Natasha L et al. (2017) G?s signalling of the CB1 receptor and the influence of receptor number. Br J Pharmacol 174:2545-2562
Ruehle, Sabine; Wager-Miller, James; Straiker, Alex et al. (2017) Discovery and characterization of two novel CB1 receptor splice variants with modified N-termini in mouse. J Neurochem 142:521-533
Hua, Tian; Vemuri, Kiran; Nikas, Spyros P et al. (2017) Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature 547:468-471
Dhopeshwarkar, Amey; Murataeva, Natalia; Makriyannis, Alex et al. (2017) Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists. J Pharmacol Exp Ther 360:300-311

Showing the most recent 10 out of 196 publications